FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs

The U.S. Food and Drug Administration (FDA) is reassessing a decision to ban compounding pharmacies to supply cheaper versions of Eli Lilly And Co’s (NYSE:LLY) blockbuster weight loss and diabetes drugs. What Happened: Reuters highlighted how the FDA had banned compounding pharmacies to supply cheaper versions of the medication, but is now reconsidering that decision. The compounding groups Outsourcing Facilities Association and FarmaKeio Custom ...